Bradley McGregor, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses prospects for various therapeutic combinations in renal cell carcinoma (RCC). Dr McGregor speaks from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, on the current status of VEGF inhibitor/immunotherapy combinations. While awaiting for data on particular drug combinations, Dr McGreggor discusses the results that have emerged for the combination of nivolumab and ipilimumab in poor risk RCC.

свернуть